Eiftu (@eiftu) header
Eiftu (@eiftu) profile picture

🇪🇹 • @UCLAUrology @UroOnc Fellow • Previously @CleClinicUro, @rushumedcollege, @CapitalOneTech HR, and @WUSTL • #BLM #YNWA #M4A

Joined April 2013
Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)Photo by Eiftu (@eiftu)
🚨 When Decipher & NCCN risk groups disagree for #ProstateCancer🚨 📖@CCR_AACR 👥 287,145 biopsy pts for molecular prevalence; DM assessed in 15,109 w/ NCCN high/very-high-risk 📊 Decipher score vs NCCN risk, + 4 adverse molecular features: TP53 mutant-like, PTEN loss, low AR activity, RB1 loss ✅Decipher showed 21% of NCCN low/favorable-intermediate pts to be high risk ✅ Decipher showed 33% of NCCN high-risk pts to be lower risk ✅ ≥1 adverse AMF + Decipher >0.60: predicted 5-yr distant met risk 17-25% vs 5% w/ favorable profile + Decipher ≤0.60 ⚠️ Retrospective cohort / correlative not randomized 🎯 TP53, PTEN loss and low AR activity drive most NCCN-Decipher discordance 🔗 doi.org/10.1158/1078-0432.CC… @UroOnc @urotoday @UrologyTimes @PCF_Science @DrSpratticus @Davicioni @angela_jia_
1
29
71
4,322
When to cut when not to cut 🗡️ can some bladders be saved and answer is yes with right biomarkers combining utDNA and ctDNA to risk stratify to surveillance surgery vs more systemic therapy nicely summarized by @BenjaminPradere #SMU26 read @EUplatinum editorial supporting this as well sciencedirect.com/science/ar…
4
15
1,731
JUST IN: @AmericanCancer (ACS) updates their guidance about routine PSA screening for #prostatecancer, moving off "shared decision-making". This is a major shift since the last ACS recommendations in 2010: 1) High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 2) Average risk: PSA every 2 years, ages 50–69. American Cancer Society 3) Non-Black men with 1 first-degree relative diagnosed ≥65: PSA every 2 years, ages 45–69. 4) Age 70–74: individualized decision; if screening continues, every 2 years. 5) Age ≥75: generally no screening; very healthy men 75–79 may discuss continued screening. 6) No screening ≥80 and no screening at any age with life expectancy <10 years. @CACancerJournal @DanaFarber_GU @harvardmed @OpenMedInsights Link: acsjournals.onlinelibrary.wi…
4
76
5
227
27,045
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨 @CACancerJournal 📋 Average risk: PSA every 2 yrs, ages 50-69 📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69 🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy 🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs ⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69 🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010 🔗 doi.org/10.3322/caac.70112 @UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
5
112
5
201
18,300
Our paper IMPACT UTUC is now published in @NatRevUrol: an international multidisciplinary Delphi consensus on #UTUC
doi.org/10.1038/s41585-026-0… @ricautor @RobertoContieri @LauraBukavinaMD @urodocash @PGrivasMDPhD @montypal @sonpavde @AndreaNecchi @jteoh_hk @carme_mir1
1
23
4
54
7,006
Medical students, residents, and clinical researchers rejoice—we present the beginning of the end for manual chart review. doi.org/10.1038/s41746-026-0… Our locally deployed LLM extracted 136,425 data points from 130K clinical notes with 97.5% agreement—outperforming manual review
22
81
9
572
77,350
Grateful to attend the @FocalSociety’s @UroOnc course for the next couple days! So much great learning from giants in the field. Great to be back in Cleveland with old friends and colleagues as well 🥰
1
2
2
36
3,978
Average California proposition DIARRHEA FOREVER? 54.3% YES ✅ 45.7% NO
40
3,403
70
30,137
279,095
Good morning!
7,821
61,733
3,280
911,966
11,170,003
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS
4
61
1
119
10,730
Eiftu retweeted
Original Article: Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer (phase 3 VOLGA trial) nej.md/4z7dQFm #ESMO26 | @myESMO
1
33
102
15,271
PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday #ESMO26 Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306) 🚨EFS: HR 0.38, 95% CI 0.26–0.55 🚨MFS: HR 0.49, 95% CI 0.26–0.90 🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43 🚨All Gr Hot Flush: 64% vs 0.7%
4
56
5
124
16,981
It has been nearly 5 months since the FDA approved durvalumab + BCG for “BCG-naïve” high-risk #NMIBC based on the POTOMAC trial. There has been considerable discussion about the discordant results of the recent phase III trials evaluating BCG + immune checkpoint blockade. But I think we're overlooking a potentially important difference between these trials, one that could have major implications for how we interpret the results and counsel our patients. POTOMAC and CREST were positive trials, but unlike the negative ALBAN trial, both permitted enrollment of patients previously treated with BCG. To my knowledge, neither has reported how many patients had prior BCG exposure or whether the benefit of adding checkpoint blockade differs between previously treated and truly BCG-naïve patients. Given the additional toxicity, treatment burden, and cost of systemic checkpoint blockade, how can we adequately counsel patients receiving BCG for the first time without knowing the magnitude of benefit specifically in patients like them? I think we need to see these subgroup data from @AstraZeneca and @pfizer . 1/n @BladderCancerUS ; @BCAN_Research ; @SUO_YUO ; @UroOnc ; @FDA ; @chana_weinstock ; @AmerUrological
3
8
3
34
4,522
This is a paper everyone needs to read .. it may ( with time and validation) change our field significantly in both NMIBC and MIBC management couple 💭 - HUGE benefit of cfRNA is 0️⃣dependence on tissue .. anyone trying to do utdna on Ta/ small focus HG/ CIS knows how valuable this is but utDNA tumor informed=cfRNA - bcg prediction is immature and underpowered but strong signal - ❗️consider false positives in here 11% in noncancer ctrl. Promising results nonetheless and better than anything we have out there .. - no validation / testing post tmt the most difficult cohort for surveillance with urine based testing and that is why we @CleClinicUro are excited to partner with @max_diehn and ReseroBio to continue their validation
Urine cfRNA is emerging as a powerful bladder cancer biomarker: 95% sensitivity at 90% specificity, with potential for MRD detection and BCG-response prediction. Prospective validation comes next. @NatureMedicine @OncoAlert @OpenMedicineHQ @isliquidbiopsy
5
21
1
76
7,793
When "cancer" is a diagnosis but not really a disease A slightly more philosophical piece than my usual—on what we mean by cancer, and whether the word itself can sometimes do more harm than good.... let me know what you think! Many thanks @pam3001 @aeonmag aeon.co/essays/we-need-a-bet…
8
18
4
63
18,628
Your patient has had nephrectomy for high-risk clear cell RCC. The next decision: Surveillance, Pembrolizumab, or Pembrolizumab + belzutifan. Is adjuvant justified when surgery may already have been curative? Our new commentary explores this dilemma. 🧵bit.ly/4jkism6
2
14
1
50
7,873
Important change in the 2026 @AmerUrological NMIBC Guidelines: all high-grade Ta tumors are now classified as high-risk. This reduces a long-standing source of heterogeneity in the intermediate-risk group and should improve risk-appropriate treatment for patients, while creating cleaner, more meaningful populations for clinical trials. Great to see the evidence translate into practice. @IBCG_BladderCA @UrogerliMD @pjhensley11 @AmirHorowitz @mouwlab @spsutkaMD @shilpaonc @AndreaNecchi @LAUrology_NL @karima_oualla @PGrivasMDPhD @marigfern @SpiessPhilippe @UroCancerMD
Time to revisit something I’ve been saying for years: TaHG bladder cancer is not intermediate risk. The clinical outcomes, molecular biology ... all point in the same direction. Yet some frameworks allow < 3cm TaHG tumors to be downgraded into “intermediate risk” alongside low-grade disease. That classification has real consequences for patients: • undertreatment • less rigorous surveillance • in some studies, these patients are even placed on observation as a supposedly appropriate “control arm.” TaHG is high risk. 🧵 @BladderCancerUS @WorldBladderCan @IBCG_BladderCA
2
30
3
97
12,072
🚨 Start ADT + ARPI & metabolic dysfunction follows, often in just a few months🚨 @JAMAOnc 👥 16,924 men w/ #ProstateCancer starting ADT + ARPI, no prior metabolic dx 📊 12-mo cumulative incidence: 🔺 New HTN 83% 🔺 Dyslipidemia 52% 🔺 Metabolic syndrome 39% ⏱️ Median time to 1st abnormality: 1 mo. MetS: 2.6 mo 🔗 doi.org/10.1001/jamaoncol.20… @AmerUrological @PCFnews @PCF_Science @UroOnc @UrologyTimes @urotoday @renalandurology
3
35
2
69
5,520
Big week for #prostatecancer news @JAMA_current! First @grace_syl for PROFOUND-VET: use of #activesurveillance is now 93% for low-risk disease and 62% for favorable intermediate. Huge news and proof that @VeteransHealth is leading the way in this area. dx.doi.org/10.1001/jama.2026…
3
36
5
101
17,482
🚨 Half of focal therapy for #ProstateCancer in the US is happening where no guideline supports it 🚨 @JAMA_current research letter 👥 1,179,384 pts w/ nonmetastatic PCa, NCDB 2010 to 2023 📊 15,672 (1.3%) got focal therapy ⚠️ 51% was in low, high, or very high risk disease. -No guideline supports routine use in ANY risk group outside trials or registries ⚠️ Low risk held flat (1.8% to 2.2%) and favorable intermediate is rising (2.1% to 2.9%) while marketing and&reimbursement expand ⚠️ Focal therapy more likely w/ age ≥75 (adjusted probability 22.9%), community centers (7.6% vs 2.5% academic), nonprivate insurance ✒️From the accompanying editorial "Volume of this kind shows diffusion, not benefit." 🎯 Key points 1⃣In low risk this converts surveillance candidates into procedure pts 2⃣In high risk it is undertreatment. 3⃣Repeated use is building "an aura of legitimacy the data have not earned." We owe pts trials, not marketing. 🔗 Study: doi.org/10.1001/jama.2026.12… 🔗 Editorial: doi.org/10.1001/jama.2026.16… @QDTrinh @DrSpratticus @AmerUrological @UroOnc @SUO_YUO @urotoday @UrologyTimes @PCF_Science @PCFnews
7
33
4
63
28,862